Bicara Therapeutics Inc
BCAXHealthcare|Biotechnology|USA
$28.88
-0.77 (-2.59%)
Tangible Book
$7.84
Financials
Financial Snapshot
Market Cap
$1.90B
Enterprise Value
$538.3M
Revenue (TTM)
$0.00
Net Income (TTM)
$-157.3M
Cash & Equivalents
—
Net Cash/Share
$7.63
Free Cash Flow (TTM)
$-116.3M
Operating CF (TTM)
$-116.2M
Debt/Equity
0
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$29.1M
Monthly Burn
$9.7M
Est. Runway
—
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $4.2M | $230.4M | $489.7M | $414.8M | $539.8M | |
| Operating Cash Flow | $-32.1M | $-45.6M | $-74.8M | $-106.8M | $-116.2M | |
| Free Cash Flow | $-32.3M | $-46.2M | $-74.8M | $-107.1M | $-116.5M | |
| Capital Expenditure | $-192.0K | $-586.0K | $-71.0K | $-280.0K | $-298.0K | |
| Financing Cash Flow | $31.7M | $272.5M | $334.0M | $32.3M | $195.1M |
R&D Spending
R&D (TTM)
$138.3M
R&D Intensity
—
R&D Growth YoY
+10.5%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $31.3M | $30.6M | $63.6M | $125.1M | $138.3M | |
| R&D % of Revenue | — | — | — | — | — | |
| SG&A | $6.3M | $9.3M | $18.8M | $30.5M | $35.8M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $31.3M | $30.6M | $63.6M | $125.1M | $138.3M | |
| SG&A | $6.3M | $9.3M | $18.8M | $30.5M | $35.8M | |
| Operating Income | $-37.7M | $-39.9M | $-82.4M | $-155.6M | $-174.1M | |
| Interest Expense | $-112.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-37.8M | $-52.0M | $-67.8M | $-137.7M | $-157.1M | |
| Net Income | $-37.8M | $-52.0M | $-68.0M | $-137.9M | $-157.3M | |
| EPS (Diluted) | -2.45 | -1.53 | -4.05 | -2.52 | -2.78 | |
| EBITDA | $-37.7M | $-39.9M | $-82.3M | $-155.5M | $-173.9M | |
| Shares Out. (M) | 15.44 | 33.98 | 16.81 | 54.68 | 60.72 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $230.4M | $489.7M | $96.7M | $323.5M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $318.1M | $216.3M | |
| Total Current Assets | $5.0M | $231.1M | $502.5M | $422.1M | $544.9M | |
| Total Assets | $6.7M | $234.0M | $510.0M | $431.0M | $553.6M | |
| Total Current Liabilities | $23.9M | $15.1M | $18.0M | $28.9M | $39.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $105.5M | $382.8M | $18.1M | $29.5M | $39.6M | |
| Stockholders' Equity | $-98.8M | $-148.8M | $491.9M | $401.5M | $514.0M | |
| Retained Earnings | $-101.0M | $-153.0M | $-221.0M | $-359.0M | $-415.2M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $-32.1M | $-45.6M | $-74.8M | $-106.8M | $-116.2M | |
| Capital Expenditure | $-192.0K | $-586.0K | $-71.0K | $-280.0K | $-298.0K | |
| Free Cash Flow | $-32.3M | $-46.2M | $-74.8M | $-107.1M | $-116.5M | |
| Investing Cash Flow | $-192.0K | $-586.0K | $-9.0K | $-318.5M | $-217.5M | |
| Financing Cash Flow | $31.7M | $272.5M | $334.0M | $32.3M | $195.1M | |
| Issuance of Stock | $0.00 | $0.00 | $332.4M | $29.5M | $191.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $810.0K | $1.9M | $7.4M | $15.0M | $17.4M | |
| Net Change in Cash | $-573.0K | $226.3M | $259.3M | $-393.0M | $-138.6M |
Dilution Tracker
Shares outstanding grew 293.2% over 5 years — significant dilution
Shares Outstanding
61M
5-Year Share Growth
+293.2%
Stock Issuance (TTM)
$191.3M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 15.44 | 33.98 | 16.81 | 54.68 | 60.72 | |
| YoY Change % | — | 120.1% | -50.5% | 225.3% | 11.0% | |
| Stock Issuance | $0.00 | $0.00 | $332.4M | $29.5M | $191.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $810.0K | $1.9M | $7.4M | $15.0M | $17.4M |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | 0.0% | -39.6% | -30.9% | -35.5% | |
| ROA % | -564.6% | -43.2% | -18.3% | -29.3% | -33.6% | |
| R&D / Revenue | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B3.68
Historical— / — / 3.68
Industry Med.2.93
EV/EBITDA-7.81
Historical-7.81 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$7.84
Net Current Assets
$7.710
Net-Net Working Capital
$7.63
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 1.93 | 2.37 | 3.68 | |
| EV/EBITDA | 0.00 | 0.00 | -5.58 | -3.47 | -7.81 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
N/A
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.00M | $17.54M |
| Net Income | $-220.43M | $-251.18M | $-256.77M |
| EPS | -3.53 | -3.79 | -3.48 |
| Book Value per Share | 6.21 | 3.76 | 0.61 |
| Operating Cash Flow per Share | -3.16 | -3.45 | -3.88 |
| Operating CF | $-191.87M | $-209.47M | $-235.58M |